Agios Pharmaceuticals Inc. Stock
We can see a decrease in the price for Agios Pharmaceuticals Inc.. Compared to yesterday it has lost -€0.400 (-1.630%).
With 14 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
As a result the target price of 33 € shows a positive potential of 36.36% compared to the current price of 24.2 € for Agios Pharmaceuticals Inc..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Agios Pharmaceuticals Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Agios Pharmaceuticals Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
S********** s********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Agios Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Agios Pharmaceuticals Inc. | -1.630% | 4.310% | 0.833% | -30.857% | 4.310% | -12.319% | -36.996% |
| Ironwood Pharmaceuticals | 0.000% | -7.182% | 7.006% | -23.636% | 26.316% | -68.356% | -65.361% |
| Novocure Ltd | 3.610% | 14.171% | 9.802% | -52.333% | 12.660% | -85.794% | -90.872% |
| Iovance Biotherapeutics Inc. | -5.370% | -2.096% | 9.900% | -66.279% | -11.404% | -63.286% | -95.001% |
Comments
Agios Pharmaceuticals (NASDAQ:AGIO) was given a new $40.00 price target on by analysts at Leerink Partners. They now have an "outperform" rating on the stock.
Show more
Ratings data for AGIO provided by MarketBeat
Agios Pharmaceuticals (NASDAQ:AGIO) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Show more
Ratings data for AGIO provided by MarketBeat
News
Here's Why Shares in Agios Pharmaceuticals Popped Today
Shares in Agios Pharmaceuticals (NASDAQ: AGIO) soared by more than 18% as of 11 a.m. today. The move follows the company's receipt of approval from the Food and Drug Administration (FDA) for AQVESME
Why Shares in Agios Pharmaceuticals Got Crushed Today
Shares in Agios Pharmaceuticals (NASDAQ: AGIO) crashed by 50% by noontime today. The move comes as the market digests a mixed set of topline results from its Phase 3 trial (RISE UP) of its sickle
Agios (AGIO) Q2 Revenue Jumps 45%
Agios Pharmaceuticals (NASDAQ:AGIO), a biotechnology company focused on therapies for rare blood disorders, released its second quarter 2025 earnings on July 31, 2025. The headline was a notable